AR044773A1 - Proceso quimico para la fabricacion de la sal calcica del acido (e) -7- ( 4-(-fluorofenil) 6-isopropil-2-(metil(metilsulfonil)amino)pirimidin-5-il)(3r,5s)-3,5-dihidroxihept-6-enoico - Google Patents

Proceso quimico para la fabricacion de la sal calcica del acido (e) -7- ( 4-(-fluorofenil) 6-isopropil-2-(metil(metilsulfonil)amino)pirimidin-5-il)(3r,5s)-3,5-dihidroxihept-6-enoico

Info

Publication number
AR044773A1
AR044773A1 ARP040101944A ARP040101944A AR044773A1 AR 044773 A1 AR044773 A1 AR 044773A1 AR P040101944 A ARP040101944 A AR P040101944A AR P040101944 A ARP040101944 A AR P040101944A AR 044773 A1 AR044773 A1 AR 044773A1
Authority
AR
Argentina
Prior art keywords
fluorophenyl
amino
methyl
methylsulfonyl
isopropyl
Prior art date
Application number
ARP040101944A
Other languages
English (en)
Inventor
Jeffrey Norman Crabb
John Horbury
Original Assignee
Astrazeneca Uk Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=33512687&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR044773(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Uk Ltd filed Critical Astrazeneca Uk Ltd
Publication of AR044773A1 publication Critical patent/AR044773A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Reivindicación 1: Un proceso para la formación de sal de calcio del ácido (E)-7-[4-(4-fluorofenil)-6-isopropil-2-[metil(metilsulfonil)amino]piridin-5-il](3R,5S)-3,5-dihidroxihept-6-enoico, caracterizado porque comprende los pasos a) a g): a) reacción de un (1-6C)alquiléster de ácido (e)-(6-{2-[4-(4-fluorofenil)-6-isopropil-2-[metil(metilsulfonil)amino]pirimidin-5-il]vinil}(4R,6S)-2,2-dimetil[1,3]dioxan-4-il)acético en un solvente orgánico miscible en agua con ácido acuoso a una temperatura elevada; b) reacción de la solución resultante con un hidróxido de metal alcalino acuoso y lavado opcional de la solución acuosa de sal de metal alcalino con un solvente orgánico adecuado; c) ajuste del pH de la solución resultante a entre pH6 y pH11; d) eliminación del solvente orgánico miscible en agua; e) filtración opcional de la mezcla resultante; f)adición de una sal de calcio soluble en agua al filtrado para formar sal de calcio del ácido (E)-7-[4-(4-fluorofenil)-6-isopropil-2-[metil(metilsulfonil)amino]pirimidin-5-il](3R,5S)-3,5-dihidroxihept-6-enoico; y g) aislamiento del producto del paso f).
ARP040101944A 2003-06-05 2004-06-04 Proceso quimico para la fabricacion de la sal calcica del acido (e) -7- ( 4-(-fluorofenil) 6-isopropil-2-(metil(metilsulfonil)amino)pirimidin-5-il)(3r,5s)-3,5-dihidroxihept-6-enoico AR044773A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0312896.4A GB0312896D0 (en) 2003-06-05 2003-06-05 Chemical process
GBGB0324793.9A GB0324793D0 (en) 2003-06-05 2003-10-24 Chemical process

Publications (1)

Publication Number Publication Date
AR044773A1 true AR044773A1 (es) 2005-10-05

Family

ID=33512687

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP040101944A AR044773A1 (es) 2003-06-05 2004-06-04 Proceso quimico para la fabricacion de la sal calcica del acido (e) -7- ( 4-(-fluorofenil) 6-isopropil-2-(metil(metilsulfonil)amino)pirimidin-5-il)(3r,5s)-3,5-dihidroxihept-6-enoico

Country Status (26)

Country Link
US (1) US8063213B2 (es)
EP (1) EP1633727B1 (es)
JP (1) JP4651615B2 (es)
KR (1) KR101099934B1 (es)
CN (1) CN100422157C (es)
AR (1) AR044773A1 (es)
AT (1) ATE464297T1 (es)
AU (1) AU2004245291B2 (es)
BR (1) BRPI0410922B8 (es)
CA (1) CA2527314C (es)
CO (1) CO5640116A2 (es)
DE (1) DE602004026576D1 (es)
ES (1) ES2341858T3 (es)
GB (2) GB0312896D0 (es)
HK (1) HK1087405A1 (es)
IL (1) IL172075A (es)
IS (1) IS2751B (es)
MX (1) MXPA05013128A (es)
MY (1) MY140820A (es)
NO (1) NO332971B1 (es)
NZ (1) NZ543962A (es)
RU (1) RU2361864C2 (es)
SA (1) SA04250223B1 (es)
TW (1) TWI341310B (es)
UY (1) UY28341A1 (es)
WO (1) WO2004108691A1 (es)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0003305D0 (en) 2000-02-15 2000-04-05 Zeneca Ltd Pyrimidine derivatives
GB0011120D0 (en) 2000-05-09 2000-06-28 Avecia Ltd Process
NL1015744C2 (nl) 2000-07-19 2002-01-22 Dsm Nv Werkwijze voor de bereiding van 2-(6-gesubstitueerde-1,3-dioxan-4-yl) azijnzuurderivaten.
DK1417180T3 (da) 2001-07-13 2007-04-10 Astrazeneca Uk Ltd Fremstilling af aminopyrimidinforbindelser
EP1323717A1 (en) 2001-12-27 2003-07-02 Dsm N.V. Process for the preparation of 2-(6-Substituted-1,3-Dioxane-4-yL) acetic acid derivatives
EP1375493A1 (en) 2002-06-17 2004-01-02 Dsm N.V. Process for the preparation of an dioxane acetic acid ester
GB0218781D0 (en) 2002-08-13 2002-09-18 Astrazeneca Ab Chemical process
DK1578731T3 (da) 2002-12-16 2010-02-15 Astrazeneca Uk Ltd Fremgangsmåde til fremstilling af pyrimidinforbindelser
GB0312896D0 (en) 2003-06-05 2003-07-09 Astrazeneca Ab Chemical process
UY28501A1 (es) * 2003-09-10 2005-04-29 Astrazeneca Uk Ltd Compuestos químicos
GB0322552D0 (en) 2003-09-26 2003-10-29 Astrazeneca Uk Ltd Therapeutic treatment
GB0324791D0 (en) * 2003-10-24 2003-11-26 Astrazeneca Ab Chemical process
US7851624B2 (en) 2003-12-24 2010-12-14 Teva Pharamaceutical Industries Ltd. Triol form of rosuvastatin and synthesis of rosuvastatin
WO2005077917A1 (en) * 2004-01-19 2005-08-25 Ranbaxy Laboratories Limited Amorphous salts of rosuvastatin
GB0428328D0 (en) 2004-12-24 2005-02-02 Astrazeneca Uk Ltd Chemical process
CA2591439C (en) * 2005-02-22 2013-03-26 Teva Pharmaceutical Industries Ltd. Rosuvastatin and salts thereof free of rosuvastatin alkylether and a process for the preparation thereof
CA2611920C (en) 2005-06-24 2015-05-05 Lek Pharmaceuticals D.D. Process for preparing pure amorphous rosuvastatin calcium
CZ299215B6 (cs) * 2005-06-29 2008-05-21 Zentiva, A. S. Zpusob výroby hemivápenaté soli (E)-7-[4-(4-fluorofenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl] (3R,5S)-3,5-dihydroxy-6-heptenovékyseliny
GB0514078D0 (en) * 2005-07-08 2005-08-17 Astrazeneca Uk Ltd Chemical process
WO2007022488A2 (en) 2005-08-16 2007-02-22 Teva Pharmaceutical Industries Ltd. Crystalline rosuvastatin intermediate
CA2619867A1 (en) * 2005-08-16 2007-02-22 Teva Pharmaceutical Industries Ltd. Rosuvastatin calcium with a low salt by-product content
HU227696B1 (en) * 2006-04-13 2011-12-28 Egyt Gyogyszervegyeszeti Gyar Zinc salt of rosuvastatin, process for its preparation and pharmaceutical compositions containing it
ES2564250T3 (es) 2006-05-03 2016-03-21 Msn Laboratories Private Limited Nuevo proceso para estatinas y sus sales farmacéuticamente aceptables de las mismas
HUE028475T2 (en) 2006-10-09 2016-12-28 Msn Laboratories Private Ltd A novel process for the preparation of statins and their pharmaceutically acceptable salts
TW200831469A (en) * 2006-12-01 2008-08-01 Astrazeneca Uk Ltd Chemical process
HU230981B1 (hu) * 2007-10-12 2019-08-28 Egis Gyógyszergyár Nyilvánosan Működő Részvénytársaság Eljárás rosuvastatin só előállítására
CA2725052C (en) 2008-05-27 2014-09-16 Changzhou Pharmaceutical Factory Co., Ltd. Preparation method of rosuvastatin calcium and its intermediates
SI2309992T1 (en) 2008-06-27 2018-03-30 Krka, Tovarna Zdravil, D.D., Novo Mesto A pharmaceutical composition comprising a statin
EP2138165A1 (en) 2008-06-27 2009-12-30 KRKA, tovarna zdravil, d.d., Novo mesto Pharmaceutical composition comprising a statin
WO2010029561A1 (en) * 2008-09-09 2010-03-18 Biocon Limited A process for preparation of rosuvastatin acetonide calcium
EP2373609B1 (en) 2008-12-19 2013-10-16 KRKA, D.D., Novo Mesto Use of amphiphilic compounds for controlled crystallization of statins and statin intermediates
EP2327682A1 (en) 2009-10-29 2011-06-01 KRKA, D.D., Novo Mesto Use of amphiphilic compounds for controlled crystallization of statins and statin intermediates
WO2010089770A2 (en) 2009-01-19 2010-08-12 Msn Laboratories Limited Improved process for the preparation of highly pure (3r,5s)-7-[2-cyclopropyl-4-(4-fluorophenyl) quinolin-3-yl]-3,5-dihydroxy-6(e)-heptenoic acid and pharmaceutically acceptable salts thereof
WO2011086584A2 (en) 2010-01-18 2011-07-21 Msn Laboratories Limited Improved process for the preparation of amide intermediates and their use thereof
US8536330B2 (en) 2010-04-23 2013-09-17 Ranbaxy Laboratories Limited Intermediates for the preparation of HMG-CoA reductase inhibitors
WO2012011129A2 (en) * 2010-07-22 2012-01-26 Msn Laboratories Limited Novel polymorph of bis[(e)-7-[4-(4-fluorophenyl)-6-iso-propyl-2-[methyl (methylsulfonyl)amino]pyrimidin-5-yl](3r,5s)-3,5-dihydroxyhept-6-enoic acid] calcium salt
CN105753834B (zh) * 2016-03-25 2018-08-21 河南师范大学 一种瑞舒伐他汀钙关键手性中间体的合成方法

Family Cites Families (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4645858A (en) 1982-03-22 1987-02-24 G. D. Searle & Co. Pentanedioic acid derivatives
DE3741509A1 (de) 1987-12-08 1989-06-22 Hoechst Ag Verfahren zur herstellung optisch aktiver 3-desmethylmevalonsaeurederivate sowie zwischenprodukte
EP0367895A1 (en) 1988-10-06 1990-05-16 Sandoz Ag Pyrimidinyl-substituted hydroxyacids, lactones and esters and pharmaceutical compositions containing them
US5026698A (en) 1988-11-02 1991-06-25 Nissan Chemical Industries, Ltd. Thienopyridine type mevalonolactones
JP2648897B2 (ja) 1991-07-01 1997-09-03 塩野義製薬株式会社 ピリミジン誘導体
WO1993008823A1 (en) 1991-11-06 1993-05-13 Tanabe Seiyaku Co., Ltd. Guanidinyl and related cell adhesion modulation compounds
US5278313A (en) 1992-03-27 1994-01-11 E. R. Squibb & Sons, Inc. Process for the preparation of 1,3-dioxane derivatives useful in the preparation of HMG-COA reductase inhibitors
ES2106926T3 (es) 1992-07-02 1997-11-16 Hoechst Ag Procedimiento para la preparacion del ester terc-butilico del acido (3r,5s)6-hidroxi-3,5-o-isopropiliden-3,5-dihidroxi-hexanoico.
ES2167587T3 (es) 1995-07-17 2002-05-16 Warner Lambert Co Forma cristalina de la sal hemicalcica del acido (r-(r*,r*))-2-(4-fluorofenil)-beta,delta-dihidroxi-5-(1-metiletil)-3-fenil-4-((fenilamino)carbonil)-1h-pirrol-1-heptanoico (atorvastatina).
US6278001B1 (en) 1995-11-28 2001-08-21 L'oréal Method for preparing (+) compactin and (+) mevinolin analog compounds having a β-hydroxy-δ-lactone grouping
FR2741620B1 (fr) 1995-11-28 1997-12-26 Oreal Procede de preparation de composes a groupement beta-hydroxy -delta-lactone analogues de la (+) compactine et de la (+) mevinoline
US6124340A (en) 1996-06-24 2000-09-26 Astra Aktiebolag Polymorphic compounds
HUP0103021A3 (en) 1998-12-10 2002-04-29 Kaneka Corp Process for producing simvastatin derivatives
GB9900339D0 (en) 1999-01-09 1999-02-24 Zeneca Ltd Chemical compounds
GB9903472D0 (en) 1999-02-17 1999-04-07 Zeneca Ltd Chemical process
WO2001022962A1 (en) 1999-09-30 2001-04-05 Merck & Co., Inc. Anti-hypercholesterolemic drug combination
JP2003514798A (ja) 1999-11-17 2003-04-22 テバ ファーマシューティカル インダストリーズ リミティド アトルバスタチンカルシウムの多形
GB0001621D0 (en) 2000-01-26 2000-03-15 Astrazeneca Ab Pharmaceutical compositions
GB0003305D0 (en) 2000-02-15 2000-04-05 Zeneca Ltd Pyrimidine derivatives
WO2001072706A1 (en) 2000-03-28 2001-10-04 Biocon India Limited Synthesis of [r-(r*,r*)]-2-(4-fluorophenyl)-beta,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid hemi calcium salt (atorvastatin)
GB0011120D0 (en) 2000-05-09 2000-06-28 Avecia Ltd Process
GB0011163D0 (en) 2000-05-10 2000-06-28 Astrazeneca Ab Chemical compound
NL1015744C2 (nl) 2000-07-19 2002-01-22 Dsm Nv Werkwijze voor de bereiding van 2-(6-gesubstitueerde-1,3-dioxan-4-yl) azijnzuurderivaten.
SK5232003A3 (en) 2000-10-05 2004-06-08 Biogal Gyogyszergyar Pravastatin sodium substantially free of pravastatin lactone and epi-pravastatin, and compositions containing same
AU2002232891B2 (en) 2000-11-16 2006-12-14 Teva Pharmaceutical Industries Ltd. Hydrolysis of [R(R*,R*)]-2-(4-fluorophenyl)-beta,delta -dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino) carbonyl]-1H-pyrrole-1-heptanoic acid esters with calcium hydroxide
IL156055A0 (en) 2000-11-30 2003-12-23 Teva Pharma Novel crystal forms of atorvastatin hemi calcium and processes for their preparation as well as novel processes for preparing other forms
NL1017548C2 (nl) 2001-03-09 2002-09-10 Synthon Bv Een lactonisatie proces.
IN190564B (es) 2001-04-11 2003-08-09 Cadila Heathcare Ltd
IL158525A0 (en) 2001-06-06 2004-05-12 Bristol Myers Squibb Co A process for preparing chiral diol sulfone derivatives
DK1417180T3 (da) 2001-07-13 2007-04-10 Astrazeneca Uk Ltd Fremstilling af aminopyrimidinforbindelser
KR20040026705A (ko) 2001-08-16 2004-03-31 테바 파마슈티컬 인더스트리즈 리미티드 스타틴의 칼슘 염 형태의 제조 방법
IL160077A0 (en) 2001-08-16 2004-06-20 Teva Pharma Processes for preparing calcium salt forms of statins
CA2455842A1 (en) 2001-08-22 2003-03-06 Ciba Specialty Chemicals Holding Inc. Process for the preparation of indole derivatives
CA2459926A1 (en) 2001-09-24 2003-04-03 Merck & Co., Inc. Screening and selection methods for statin drug combinations
EP1323717A1 (en) 2001-12-27 2003-07-02 Dsm N.V. Process for the preparation of 2-(6-Substituted-1,3-Dioxane-4-yL) acetic acid derivatives
KR100511533B1 (ko) 2002-04-09 2005-08-31 임광민 키랄 중간체, 그의 제조방법 및 그를 이용한 HMG-CoA환원저해제의 제조방법
AR039836A1 (es) 2002-05-21 2005-03-02 Ranbaxy Lab Ltd Proceso para la preparacion de un aldehido de pirimidina util para la preparacion de rosuvastatina
EP1375493A1 (en) 2002-06-17 2004-01-02 Dsm N.V. Process for the preparation of an dioxane acetic acid ester
GB0218781D0 (en) * 2002-08-13 2002-09-18 Astrazeneca Ab Chemical process
DE60239428D1 (es) 2002-12-10 2011-04-21 Ranbaxy Lab Ltd
DK1578731T3 (da) 2002-12-16 2010-02-15 Astrazeneca Uk Ltd Fremgangsmåde til fremstilling af pyrimidinforbindelser
BRPI0409292A (pt) 2003-04-11 2006-04-11 Lek Pharmaceuticals processo para a preparação de sal de cálcio amorfo de atorvastatina
WO2004103977A2 (en) 2003-05-21 2004-12-02 Ciba Specialty Chemicals Holding Inc. Process for the preparation of pyrimidine derivatives
GB0312896D0 (en) 2003-06-05 2003-07-09 Astrazeneca Ab Chemical process
WO2005005384A1 (en) 2003-07-15 2005-01-20 Eos Eczacibasi Ozgun Kimyasal Urunler Sanyi Ve Ticaret A.S. Process for the preparation of amortphous atorvastatin calcium without interconversion of any crystalline form
CA2537271A1 (en) 2003-08-28 2005-03-17 Teva Pharmaceutical Industries, Ltd. Process for preparation of rosuvastatin calcium
UY28501A1 (es) 2003-09-10 2005-04-29 Astrazeneca Uk Ltd Compuestos químicos
GB0321827D0 (en) 2003-09-18 2003-10-15 Astrazeneca Uk Ltd Chemical compounds
GB0322552D0 (en) 2003-09-26 2003-10-29 Astrazeneca Uk Ltd Therapeutic treatment
WO2005040134A1 (en) 2003-10-22 2005-05-06 Ranbaxy Laboratories Limited Process for the preparation of amorphous rosuvastatin calcium
GB0324791D0 (en) 2003-10-24 2003-11-26 Astrazeneca Ab Chemical process
DE10352659B4 (de) 2003-11-11 2007-09-13 Ratiopharm Gmbh Verfahren zur Herstellung von Statinen und Tetrahydropyranonderivate zur Verwendung in dem Verfahren
EP1601658A1 (en) 2003-11-24 2005-12-07 Teva Pharmaceutical Industries Limited Crystalline ammonium salts of rosuvastatin
EP1689723B1 (en) 2003-12-02 2011-04-27 Teva Pharmaceutical Industries, Ltd. Reference standard for characterization of rosuvastatin
WO2005054207A1 (en) 2003-12-04 2005-06-16 Glenmark Pharmaceuticals Limited Process for the preparation of pyrimidine derivatives
WO2005063728A2 (en) 2003-12-24 2005-07-14 Teva Pharmaceutical Industries Ltd. Process for preparation of statins with high syn to anti ratio
CZ200486A3 (cs) 2004-01-16 2005-08-17 Zentiva, A.S. Způsob výroby hemivápenaté soli (E)-7-[4-(4-fluorfenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl](3R,5S)-3,5-dihydroxy-6-heptenové kyseliny
WO2005077917A1 (en) 2004-01-19 2005-08-25 Ranbaxy Laboratories Limited Amorphous salts of rosuvastatin
EP1709008A1 (en) 2004-01-19 2006-10-11 Ranbaxy Laboratories Limited Salts of hmg-coa reductase inhibitors and use thereof
US7241800B2 (en) 2004-03-17 2007-07-10 Mai De Ltd. Anhydrous amorphous form of fluvastatin sodium
GB0406757D0 (en) 2004-03-26 2004-04-28 Avecia Ltd Process and compounds
US7161004B2 (en) 2004-06-21 2007-01-09 Dr. Reddy's Laboratories Limited Processes to produce intermediates for rosuvastatin
JP2007508379A (ja) 2004-07-13 2007-04-05 テバ ファーマシューティカル インダストリーズ リミティド Ｔｅｍｐｏ媒介型酸化段階を包含するロスバスタチンの調製方法
WO2006035277A2 (en) 2004-09-27 2006-04-06 Ranbaxy Laboratories Limited Novel processes for preparing amorphous rosuvastatin calcium and a novel polymorphic form of rosuvastatin sodium
GB0428328D0 (en) 2004-12-24 2005-02-02 Astrazeneca Uk Ltd Chemical process
US7932387B2 (en) 2005-01-31 2011-04-26 Basf Se Crystalline forms of rosuvastatin calcium salt
CA2498978A1 (en) 2005-02-28 2006-08-28 Apotex Pharmachem Inc. An improved process for the preparation of atorvastatin and intermediates
GB0514078D0 (en) 2005-07-08 2005-08-17 Astrazeneca Uk Ltd Chemical process
TW200831469A (en) 2006-12-01 2008-08-01 Astrazeneca Uk Ltd Chemical process

Also Published As

Publication number Publication date
CN1798741A (zh) 2006-07-05
SA04250223B1 (ar) 2008-12-23
US8063213B2 (en) 2011-11-22
CA2527314C (en) 2012-02-21
IL172075A (en) 2011-06-30
BRPI0410922B1 (pt) 2016-02-23
BRPI0410922A (pt) 2006-06-27
IS2751B (is) 2011-09-15
WO2004108691A1 (en) 2004-12-16
MXPA05013128A (es) 2006-03-16
RU2005138370A (ru) 2006-07-10
CA2527314A1 (en) 2004-12-16
GB0312896D0 (en) 2003-07-09
CN100422157C (zh) 2008-10-01
AU2004245291B2 (en) 2008-02-14
UY28341A1 (es) 2005-01-31
HK1087405A1 (en) 2006-10-13
ES2341858T3 (es) 2010-06-29
EP1633727A1 (en) 2006-03-15
KR101099934B1 (ko) 2011-12-28
NO20055730L (no) 2005-12-27
ATE464297T1 (de) 2010-04-15
EP1633727B1 (en) 2010-04-14
NZ543962A (en) 2008-09-26
MY140820A (en) 2010-01-29
TWI341310B (en) 2011-05-01
BRPI0410922B8 (pt) 2021-05-25
RU2361864C2 (ru) 2009-07-20
TW200510337A (en) 2005-03-16
US20080221323A1 (en) 2008-09-11
JP2006526602A (ja) 2006-11-24
CO5640116A2 (es) 2006-05-31
AU2004245291A1 (en) 2004-12-16
IS8217A (is) 2006-01-02
DE602004026576D1 (de) 2010-05-27
NO20055730D0 (no) 2005-12-05
KR20060017848A (ko) 2006-02-27
NO332971B1 (no) 2013-02-11
JP4651615B2 (ja) 2011-03-16
GB0324793D0 (en) 2003-11-26

Similar Documents

Publication Publication Date Title
AR044773A1 (es) Proceso quimico para la fabricacion de la sal calcica del acido (e) -7- ( 4-(-fluorofenil) 6-isopropil-2-(metil(metilsulfonil)amino)pirimidin-5-il)(3r,5s)-3,5-dihidroxihept-6-enoico
ES2361009T3 (es) Procedimiento para preparar la sal de calcio de rosuvastatina.
EE05288B1 (et) 7-[4-(4-fluorofenl)-6-isopropl-2-metl(metlsulfonl)amino]primidiin-5-l] -(3R,5S)-3,5- dihdrokshept-6-enohappe kristalsed soolad
UA83076C2 (en) Process for the manufacture of the calcium salt of (e)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino] pyrimidin-5-yl](3r,5s)-3,5-dihydroxyhept-6-enoic acid, intermediates and use thereof
NO20013368D0 (no) Krystallinsk bis((E)-7-(4-(4-fluorfenyl)-6-isopropyl-2- (metyl(metylsulfonyl)amino)pyrimidin-5-yl)(3R,5S)-3,5-dihydroksyhept-6-ensyre)kalsiumsalt
MY142615A (en) Crystalline form of bis [ (e)-7-4(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl](3r, 5s)-3,5-dihydroxyhept-6 -enoic acid] calcium salt
JP2003518474A5 (es)
IS6029A (is) Aðferð til framleiðslu á tert-bútýl (E)-(6-[2-[4-(4-flúorófenýl)-6-ísóprópýl-2-[metýl(metýlsúlfónýl)amínó]pýrimidín-5-ýl]vinýl](4R,6S)-2,2-dímetýl[1,3]díoxan-4-ýl)asetat
MY124784A (en) A novel crystalline form of n-[4-[2-(2-amino-4,7-dihydro-4-oxo-3h-pyrrolo [2,3-d] pyrimidin-5-yl) ethyl] benzoyl]-l-glutamic acid and proces therefor
WO2007099561A1 (en) Process for preparing rosuvastatin calcium
ATE553098T1 (de) Verfahren zur herstellung von rosuvastatin- calcium
AR043594A1 (es) Un procedimiento para la preparacion de la sal de calcio del acido (e)-7-[4-(4-fluorofenil)-6-isopropil-2-[metil(metil-sulfonil)amino]pirimidin-5-il] (3r,5s)-3,5-dihidroxihept-6-enoico y compuesto utilizable en dicho procedimiento

Legal Events

Date Code Title Description
FB Suspension of granting procedure